Hamilton Lane Advisors’s NEVRO CORP. NVRO Stock Holding History

Hamilton Lane Advisors’s Portfolio NVRO Stock Details NVRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-47,475	Closed	-$4K	–	55
2018 Q2	$4K	Buy	47,475 +37,564	+379%	+$3.12M	3.64%	8
2018 Q1	$1K	Sell	9,911 -13,310	-57%	-$1.07M	0.79%	30
2017 Q4	$1.6M	Buy	23,221 +19,905	+600%	+$1.59M	0.83%	30
2017 Q3	$301K	Sell	3,316 -1,956	-37%	-$167K	0.21%	45
2017 Q2	$392K	Sell	5,272 -5,000	-49%	-$401K	0.21%	46
2017 Q1	$962K	Sell	10,272 -15,215	-60%	-$1.38M	0.48%	37
2016 Q4	$1.85M	Buy	25,487 +6,953	+38%	+$595K	1.22%	23
2016 Q3	$1.94M	Sell	18,534 -10,726	-37%	-$969K	0.97%	28
2016 Q2	$2.04M	Sell	29,260 -30,200	-51%	-$2.05M	0.99%	21
2016 Q1	$3.35M	Sell	59,460 -20,000	-25%	-$1.18M	1.59%	15
2015 Q4	$5.36M	Sell	79,460 -20,046	-20%	-$1.07M	2.36%	11
2015 Q3	$4.62M	Sell	99,506 -30,000	-23%	-$1.45M	2.28%	13
2015 Q2	$6.96M	Buy	+129,506	New	+$6.6M	2.63%	12

Other funds holding NVRO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Hamilton Lane Advisors's NVRO Position: Q3 2018 in Review

Hamilton Lane Advisors sold out of NEVRO CORP. (NVRO) in Q3 2018, closing a stake of 47,475 shares — an estimated $4K sold.

Hamilton Lane Advisors first reported a position in NVRO in Q2 2015 and held it in 13 quarters. The position peaked at $6.96M in Q2 2015. 171 funds tracked by Wall St. Rank hold NVRO as of Q3 2018.

Hamilton Lane Advisors reported no remaining NEVRO CORP. position as of Q3 2018 after selling out during the quarter.
Hamilton Lane Advisors sold 47,475 NEVRO CORP. shares in Q3 2018, an estimated $4K.
Hamilton Lane Advisors first reported a position in NEVRO CORP. in Q2 2015 and held it in 13 quarters.
Hamilton Lane Advisors's NEVRO CORP. position peaked at $6.96M in Q2 2015.
171 funds tracked by Wall St. Rank held NEVRO CORP. as of Q3 2018.

Based on Hamilton Lane Advisors's 13F filing for Q3 2018, filed 16 Oct 2018.